Did you know Cytiva cell therapy systems, consumables, and reagents are designed-in to 6 of 7 commercialized CAR T therapies available today?*   

It's projected that by the end of 2023, more than 5500 patients will have benefited from these commercialized CAR T cell therapies using their own cells as source material*. As this number continues to grow, what steps are you taking to secure and standardize your workflow?

With closed, automated systems from Cytiva, you can secure your workflow of today — and tomorrow — to get your therapy safely to patients. 

• Reduce labor time to save cell therapy manufacturing cost 
• Streamline technology transfer with maintaining control of your process
• Speed up regulatory submission thanks to personalized support

*Data sourced by GlobalData in project completed November 2022